In his closing argument, Christopher Seeger, lead attorney for the plaintiff in the second Vioxx case to go to trial, accused Merck and Co. of concealing evidence that the drug led to heart attacks in order to protect profits.
Seeger, in closing arguments, rejected claims by the company that Vioxx did not cause the rupture of plaque in a coronary artery of his client, Frederick Humeston, 60, that triggered the heart attack